Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid™ (CC-4047) and their relationship with venous thrombosis

European Journal of Haematology

Volumn 74, Issue 4, 2005, Pages 293-296

  Streetly, Matthew ^a   Hunt, Beverley J ^a,c   Parmar, Kiran ^a   Jones, Richard ^a   Zeldis, Jerome ^b   Schey, Steve ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b CELGENE CORPORATION   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Actimid; D dimer; Myeloma; Thalidomide; Thrombosis

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; CYTOKINE; D DIMER; IMMUNOMODULATING AGENT; INTERLEUKIN 6; PROTHROMBIN; THALIDOMIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; MALE; MYELOMA; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOSIS;

EID: 16244363678     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00393.x     Document Type: Article

References (15)

1. CATOVSKY D, IKOKU NB, PITNEY WR, GALTON DA. Thromboembolic complications in myelomatosis. Br Med J 1970;3:438-439.
2. SRKALOVIC G, CAMERON MG, RYBICKI L, DEITCHER SR, KATTKE-MARCHANT K, HUSSEIN MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004;101:558-566.
3. ZANGARI M, SAGHAFIFAR F, MEHTA P, BARLOGIE B, FINK L, TRICOT G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003;29:275-282.
4. CAVENAGH JD, OAKERVEE H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003;120:18-26.
5. RAJKUMAR SV, HAYMAN S, GERTZ MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-4323.
6. FLAGEUL B, WALLACH D, CAVELIER-BALLOY B, BACHELEZ H, CARSUZAA F, DUBERTRET L. Thalidomide and thrombosis. Ann Dermatol Venereol 2000;127:171-174.
7. HIDESHIMA T, CHAUHAN D, SHIMA Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950.
8. ANDERSON KC. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002;29(6 Suppl. 17):17-20.
9. CLAUSS M, GERLACH M, GERLACH H, BRETT J, WANG F, FAMILLETTI PC, PAN YC, OLANDER JV, CONNOLLY DT, STERN D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-1545.
10. GEITZ H, HANDT S, ZWINGENBERGER K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221.
11. SCHEY SA, FIELDS P, BARTLETT JB, CLARKE IA, ASHAN G, KNIGHT RD, STREETLY M, DALGLEISH AG. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-3276.
12. ZANGARI M, ANAISSIE E, BARLOGIE B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615.
13. HORNE MK III, FIGG WD, ARLEN P, GULLEY J, PARKER C, LAKHANI N, PARNES H, DAHUT WL. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic andro gen-independent prostate cancer. Pharmacotherapy 2003;23:315-318.
14. RICHARDSON PG, SCHLOSSMAN RL, WELLER E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.
15. CAINE GJ, LIP GY, STONELAKE PS, RYAN P, BLANN AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004;92:185-190.